Plasma levels of von Willebrand factor in subjects with isolated impaired fasting glucose

Medical Science Monitor

Volumn 15, Issue 4, 2009, Pages

  Coban, Erkan ^a   Bostan, Feyzi ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Cardiovascular risk; Endothelial dysfunction; Impaired fasting glucose; von Willebrand factor

Indexed keywords

GLUCOSE; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MALE;

BLOOD GLUCOSE; CASE-CONTROL STUDIES; FASTING; HUMANS; VON WILLEBRAND FACTOR;

EID: 65949088357     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Curtis C, Wilson C: Preventing type 2 diabetes mellitus. J Am Board Fam Pract, 2005; 18: 37-43
2. Genuth S, Alberti KG, Bennett P et al: Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care, 2003; 26: 3160-3167
3. Petersen JL, McGuire DK: Impaired glucose tolerance and impaired fasting glucose - a review of diagnosis, clinical implications and management. Diab Vasc Dis Res, 2005; 2: 9-15 (Pubitemid 40333199)
4. Rijkelijkhuizen JM, Nijpels G, Heine RJ et al: High risk of cardiovascular mortality in individuals with impaired fasting glucose is explained by conversion to diabetes: the Hoorn study Diabetes Care, 2007; 30: 332-336 (Pubitemid 46198339)
5. Pankow JS, Kwan DK, Duncan BB et al: Cardiometabolic risk in impaired fasting glucose and impaired glucose tolerance: the Atherosclerosis Risk in Communities Study. Diabetes Care, 2007; 30: 325-331
6. Liu J, Grundy SM, Wang W et al: Ten-year risk of cardiovascular incidence related to diabetes, prediabetes, and the metabolic syndrome Am Heart J, 2007; 153: 552-558
7. Barzilay JI, Spiekerman CF, Kuller LH et al: Prevalence of clinical and isolated subclinical cardiovascular disease in older adults with glucose disorders: the Cardiovascular Health Study. Diabetes Care, 2001; 24: 1233-1239 (Pubitemid 33716404)
8. Fisman EZ, Motro M, Tenebaum A et al: Impaired fasting glucose concentrations in nondiabetic patients with ischemic heart disease: a marker for a worse prognosis. Am Heart J, 2001; 141: 485-490 (Pubitemid 32200280)
9. Zoghi M, Nalbantgil I: Hypertension and endothelial dysfunction. Anadolu Kardiyol Derg, 2002; 2: 142-147
10. Poredos P: Endothelial dysfunction in the pathogenesis of atherosclerosis. Int Angiol, 2002; 21: 109-116
11. Lip GY, Blann AD: Von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Cardiovasc Res, 1997; 34: 255-265 (Pubitemid 27241568)
12. Wagner DD: Cell biology of von Willebrand factor. Annu Rev Cell Biol, 1990; 6: 217-246
13. Pearson JD: Markers of endothelial cell perturbation and damage. Br J Rheumatol, 1993; 32: 651-652
14. Blann AD, Taberner DA: A reliable marker of endothelial cell dysfunction: does it exist? Br J Haematol, 1995; 90: 244-248
15. Blann Ad, McCollum CN: Von Willebrand factor and the endothelial cell damage and atherosclerosis. Eur J Vasc Surg, 1994; 8: 10-15
16. Ouwina SM, La Greca RD, Zanaro NL et al: Endothelial dysfunction, nitric oxide and platelet activation in hypertensive and diabetic type II patients. Thromb Res, 2001; 102: 107-114 (Pubitemid 32373219)
17. Heywood DM, Mansfield MW, Grant PJ: Levels of von Willebrand factor, insulin resistance syndrome, and a common vWF gene polymorphism in non-insulin-dependent (type 2) diabetes mellitus. Diabet Med, 1996; 13: 720-725 (Pubitemid 26252950)
18. Seligman BG, Biolo A, Polanczyk CA et al: Increased plasma levels of endothelin 1 and von Willebrand factor in patients with type 2 diabetes and dyslipidemia. Diabetes Care, 2000; 23: 1395-1400
19. Alberti KM, Zimmet P, Shaw J; for the IDF Epidemiology Task Force Consensus Group: The metabolic syndrome - a new worldwide definition. Lancet, 2005: 366; 1059-1062
20. Friedewald WT, Levi RI, Fredricksen DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem, 1972; 18: 499-502
21. Blake DR, Meigs CB, Muller DC et al: Impaired glucose tolerance, but not impaired fasting glucose, is associated with increased levels of coronary heart disease risk factors: results from the Baltimore Longitudinal Study on Aging. Diabetes, 2004; 53: 2095-2100 (Pubitemid 38970760)
22. Tominaga M, Eguchi H, Manaka H et al: Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care, 1999, 22: 920-924
23. Bjørnholt JV, Erikssen G, Aaser E et al: Fasting blood glucose: an underestimated risk factor for cardiovascular death. results from a 22-year follow-up of healthy diabetic men. Diabetes Care, 1999; 22: 45-49
24. Balkau B, Bertrais S, Ducimetiere P, Eschwege E: Is there a glycemic threshold for mortality risk? Diabetes Care, 1999; 22: 696-769 (Pubitemid 29220766)
25. DECODE Study Group, the European Diabetes Epidemiology Group: Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care, 2003; 26: 688-696
26. Scheidt-Nave C, Barrett-Connor E, Wingard DL et al: Sex differences in fasting glycemia as a risk factor for ischaemic heart disease death. Am J Epidemol, 1991; 133: 565-576
27. Wen CP, Cheng TY, Tsai SP et al: Increased mortality risks of pre-diabetes (impaired fasting glucose) in Taiwan. Diabetes Care, 2005; 28: 2756-2761
28. Ibrahim HA, El-Meligi AA, Abdel-Hamid M, Elhendy A: Relations between von Willebrand factor, markers of oxidative stress and microalbuminuria in patients with type 2 diabetes mellitus. Med Sci Monit, 2004; 10(3): CR85-89 (Pubitemid 38339029)
29. Morise T, Takeuchi Y, Kawano M et al: Increased plasma levels of immunoreactive endothelin and von Willebrand factor in NIDDM patients. Diabetes Care, 1995; 18: 87-89
30. Seligman BG, Biolo A, Polancyzk CA et al: Increased plasma levels of endothelin 1 and von Willebrand factor in patients with type 2 diabetes and dyslipidaemia. Diabetes Care, 2000; 23: 1395-1400
31. Gaede P, Vedel P, Parving HH, Pedersen O: Elevated levels of plasma von Willebrand factor and the risk of micro-and macrovascular disease in type 2 diabetic patients with microalbuminuria. Nephrol Dial Transplant, 2001; 16: 2028-2033
32. Vehkavaara S, Seppala-Lindroos A, Westerbacka J et al: In vivo endothelial dysfunction characterizes patients with impaired fasting glucose. Diabetes Care, 1999; 22: 2055-2060
33. Meigs JB, Mittleman MA, Nathan DM et al: Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA, 2000; 283: 221-228 (Pubitemid 30039222)
34. Deadwania PC: Diabetes is a vascular disease: the role of endothelial dysfunction in pathophysiology of cardiovascular disease in diabetes. Cardiol Clin, 2004; 22: 505-509
35. Hamilton SJ, Chew GT, Watts GF: Therapeutic regulation of endothelial dysfunction in type 2 diabetes mellitus. Diab Vasc Dis Res, 2007; 4: 89-102